EGFR and cancer: Monoclonal immunoglobulin fractions with binding-avidity for trophic membrane receptors that are over-expressed by neoplastic cell types including HER2/neu (e.g. anti-HER2/neu: trastuzumab, pertuzumab),[15–19] EGFR (e.g. anti-EGFR: cetuximab, gefitinib), [20–23] both HER2/neu and EGFR (e.g. anti-HER2/neu and anti-EGFR: panitumumab),[22–25] and IGFR (e.g. figitumumab, dalotuzumab)[26–29] can all be effective treatment options for cancer including forms of neoplasia affecting the breast, intestinal tract, lung and prostate.